Company Insights

SSII customer relationships

Explore interactive graphBrowse insights index

SSII customers relationship map

SS Innovations International (SSII): Customer Footprint and Commercial Signals for Investors

SS Innovations International designs, manufactures and sells the SSi Mantra surgical-robotic system and monetizes through three primary revenue streams: outright hardware sales, deferred/installment contracts (3–5 year tenor), and usage-based pay-per-procedure arrangements that create recurring service and consumable revenue. The company sells directly to large multi‑specialty hospitals and through distributors, and is converting product capability—particularly telesurgery—into commercial traction both in India and in selected international markets.

For a quick company reference, visit the Null Exposure homepage: https://nullexposure.com/

Where SSII’s robots are being used today — installations and telesurgery partners

The following captures every customer relationship reported in public sources between FY2024–FY2026. Each entry gives the plain-English commercial fact and the public source.

World Laparoscopy Hospital

SS Innovations installed an SSi Mantra robotic system at the World Laparoscopy Hospital, a prominent minimal‑access surgery training institute in India, signaling adoption in teaching and training centers where surgeon throughput is high. Source: GlobeNewswire company update (April 22, 2024).

Preeti Urology & Kidney Hospitals

A remote pediatric pyeloplasty was performed with a surgeon operating from SSII’s Gurugram headquarters while the 16‑month‑old patient was at Preeti Hospital in Hyderabad—evidence of SSII’s telesurgery capabilities being used for complex urological procedures. Source: The Robot Report (FY2025).

Manipal Hospital (Jaipur)

A cardiac surgeon used SSII’s Tele Surgeon Console remotely to perform a robot‑assisted coronary artery bypass on a patient at Manipal Hospital in Jaipur, showing the system is deployed for high‑acuity cardiovascular operations beyond routine general surgery. Source: The Robot Report (FY2025).

HER Health Hospital (Bhopal)

HER Health Hospital participated in an inter‑hospital telesurgery program in which multiple complex gynecological procedures were performed remotely using the SSi MantrAsana Tele Surgeon Console, illustrating the console’s role in extending specialist coverage across cities. Source: GlobeNewswire press release on SSi Mantra approvals (March 18, 2026) and related coverage.

Mohak Bariatrics and Robotics (Indore)

Mohak Bariatrics performed 13 gastric bypass procedures remotely using SSII’s teleconsole during an eight‑hour inter‑hospital telesurgery session, demonstrating both volume throughput and a pay-per-procedure use case for bariatric surgery. Source: GlobeNewswire press release (March 18, 2026) and corroborating capital markets coverage.

Aster Hospital, Dubai

SSII completed its first international order for the SSi Mantra with delivery to Aster Hospital in Dubai in August 2023, marking the company’s initial commercial export and the start of EMEA deployments. Source: TheWeek health coverage (January 27, 2024).

Aster DM Healthcare (Bengaluru)

SSII’s Mantra performed an ultra‑low anterior resection for rectal cancer at Aster DM Healthcare in Bengaluru in October 2023, demonstrating applicability in complex colorectal oncology procedures and adoption by a major multi‑hospital operator. Source: TheWeek health coverage (January 27, 2024).

What these customer ties reveal about SSII’s commercial model

These relationships collectively illustrate a hybrid commercial posture:

  • Contracting posture — longer duration and diversified monetization: Company disclosures indicate customers buy SSi Mantra via outright purchase, deferred installment plans (balances paid over 3–5 years), and pay‑per‑procedure arrangements where revenue is recognized over time. This gives SSII a mix of upfront cash and recurring revenue streams tied to procedure volume. (Company filings and public disclosures.)

  • Customer concentration and target profile: Sales and marketing focus on large, multi‑specialty hospitals and training centers capable of high procedural volumes; revenues are concentrated in APAC with India accounting for the vast majority of sales historically. This creates scale advantages for installs but also concentration risk tied to Indian demand. (Company revenue by geography; FY2024–FY2025 disclosures.)

  • Commercial criticality and product maturity: Deployments for cardiac, colorectal, bariatric and complex gynecological procedures indicate the system is commercial‑stage and used for high‑acuity care, making installed systems critical to hospital surgical capability rather than optional adjuncts. Regulatory approvals for telesurgery in markets such as Indonesia and the Philippines expand addressable markets and enable remote service models. (Company press releases, Mar 2026.)

  • Manufacturing and control: SSII designs and manufactures the SSi Mantra in‑house in India, so product control and margins are concentrated within the company, but scaling manufacturing will be essential to match adoption. (Company product and manufacturing disclosures.)

Risk and upside — what investors should focus on

  • Upside: The pay‑per‑procedure model converts device adoption into recurring, high‑margin revenue tied to clinical volume; telesurgery penetration unlocks new hospital customers without duplicative capital sales, accelerating reach. The company’s early international orders (Dubai) demonstrate export capability and regulatory progress. Widespread adoption in multi‑hospital systems could materially expand revenue per installed base.

  • Risk: Revenue concentration in India is high (over 90% historically), creating geographic concentration risk as SSII scales internationally. Sales depend on hospital capital budgets and surgeon training cycles; deferred payment terms (3–5 years) lengthen cash conversion when installations are financed. High insider ownership and low institutional ownership also affect liquidity and governance dynamics. Contract tenor and customer concentration are primary near‑term risks to watch.

How to monitor progress from here

  • Track quarterly disclosure of procedure counts under pay‑per‑procedure contracts and any disclosures on installed base growth outside India.
  • Watch follow‑up press releases on telesurgery sessions and regulatory approvals in new markets; those are leading indicators of international recurring revenue.
  • Observe cash collection patterns given deferred payment contracts and whether SSII secures distributor partnerships to accelerate international scale.

For a concise dashboard of SSII’s commercial relationships and signals, visit Null Exposure: https://nullexposure.com/

Conclusion

SS Innovations has moved from product validation to commercial deployment across teaching hospitals, large multispecialty groups and early international buyers. The combination of deferred sales, usage‑based contracts and telesurgery capability creates a compelling path from hardware sales to recurring revenue, but the stock’s outlook will be decided by geographic diversification, conversion of installed systems into procedure volume, and the company’s ability to scale manufacturing and service globally.

Join our Discord